However, little is known about whether an SGLT2 inhibitor can prevent cardiac fibrosis and inhibit the TGF-β1/Smad pathway in a normoglycemic animal model of chronic heart failure (CHF). The gene discussed is TGFB1; the disease is congestive heart failure.